Antibody Drug Conjugates (ADCs) – An Emerging Treatment Platform in Lung Cancer

episode

Conversations in Lung Cancer Research not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

A.I. Safety Goes Mainstream + a ‘Hard Fork’ Exit AMA 1h 25m · 18 Sep 2026 · Hard Fork

Layoffs at the Kansas City Star will hurt local communities 15 min · 18 Sep 2026 · Kansas City Today

AWP: Beyond the Exam Room: Purpose, Myopia, and Population Health 54 min · 17 Sep 2026 · EyeCode Media

Planning Commission Meeting - Sep 17, 2026 1h 11m · 17 Sep 2026 · Leesburg Planning Commission

Heritage Commission - Sep 14, 2026 1h 57m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Historic District Review Committee - Sep 14, 2026 1h 36m · 17 Sep 2026 · Loudoun County Board Committees and Advisory Boards

Report any issue

Source

Recorded15 Dec 2023

Publisherfeeds.simplecast.com ↗

Handlerec:1544650

Show notes

In this TOGA Podcast the speakers discuss Antibody Drug Conjugates (ADCs) – An Emerging Treatment Platform in Lung Cancer. The discussion explores the different molecules and mechanisms of drugs currently available, trial results and the subsequent place of ADCs in the Lung Cancer. Furthermore, our guests expand upon the management of patients receiving these drugs. A/Prof Melissa Moore, Medical Oncologist at St Vincent’s Hospital Melbourne, is joined in this conversation by fellow medical oncologists A/Prof Tom John from Peter MacCallum Cancer Centre in Melbourne and A/Prof Adnan Nagrial from Westmead Hospital in Sydney.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in